In the journal Neuropsychopharmacology, Yale University School of Medicine’s Gerard Sanacora and Stanford University School of Medicine’s Alan Schatzberg examine the scientific literature on ketamine, and discuss some of the promises and dangers surrounding the recent resurgence of interest in the drug as a potential treatment for depression.
“There are a number of troubling findings regarding ketamine’s pharmacology that should be given a thought,” the authors write. “First, the drug does produce dissociation and psychosis and is subject to abuse.”
The January 2015 issue of Neuropsychopharmacology includes two other freely accessible articles on the same topic.
(Full text) Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? (Sanacora, Gerard and Schatzberg, Alan. Neuropsychopharmacology. January 2015. doi:10.1038/npp.2014.261)